INTERFERON GAMMA-1A

Summary

Interferon Gamma-1A (CHEMBL2108511) is a phase-3 clinical-stage protein.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108511
Name	INTERFERON GAMMA-1A
Type	Protein
Max phase	3

Also known as: Biogamma, Imunomax, Interferon gamma-1a, SUN-4800, INTERFERON-GAMMA, INTERFERON GAMMA-1A

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	4
PHASE1	3
Not specified	3
PHASE1/PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001317	PHASE4	COMPLETED	A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood
NCT00001296	PHASE3	COMPLETED	A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
NCT00047645	PHASE3	COMPLETED	A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00052039	PHASE3	TERMINATED	A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone
NCT01270490	PHASE3	UNKNOWN	Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia
NCT01649921	PHASE3	COMPLETED	The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis
NCT00047658	PHASE2	COMPLETED	A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00052052	PHASE2	COMPLETED	An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00201123	PHASE2	COMPLETED	Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
NCT00244179	PHASE2	UNKNOWN	New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis
NCT03112590	PHASE1/PHASE2	COMPLETED	Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
NCT05065905	PHASE1/PHASE2	COMPLETED	Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
NCT00563212	PHASE1	COMPLETED	A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
NCT02197169	PHASE1	COMPLETED	DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
NCT02614456	PHASE1	COMPLETED	Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
NCT05359315	Not specified	UNKNOWN	Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
NCT05395702	Not specified	COMPLETED	Study of Ingaron’s Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia
NCT06118619	Not specified	UNKNOWN	A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).